{
    "2021-08-04": [
        [
            {
                "time": "",
                "original_text": "“20cm”涨停！芯片界“药明康德”半年报藏玄机",
                "features": {
                    "keywords": [
                        "涨停",
                        "芯片",
                        "药明康德",
                        "半年报"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "半导体",
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "中泰证券：维持药明康德(603259.SH)“买入”评级 产能快速扩张 有望驱动小分子CDMO业绩提速",
                "features": {
                    "keywords": [
                        "中泰证券",
                        "药明康德",
                        "买入",
                        "CDMO",
                        "产能扩张"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "药明康德(603259)：激励计划发布 库威基地收购落地 长期前景可期",
                "features": {
                    "keywords": [
                        "药明康德",
                        "激励计划",
                        "库威基地",
                        "收购",
                        "长期前景"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "国金证券：维持药明康德(603259.SH)“买入”评级 国内CXO产业整体保持高景气",
                "features": {
                    "keywords": [
                        "国金证券",
                        "药明康德",
                        "买入",
                        "CXO",
                        "高景气"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "药明康德(603259.)：板块高景气 CXO龙头加速成长",
                "features": {
                    "keywords": [
                        "药明康德",
                        "CXO",
                        "高景气",
                        "龙头",
                        "成长"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "药明康德(603259)事件点评：激励加码 协同加深 持续看好",
                "features": {
                    "keywords": [
                        "药明康德",
                        "激励",
                        "协同",
                        "看好"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝莱德减持药明康德(02359)98.14万股，每股作价约167.17港元 减持股份",
                "features": {
                    "keywords": [
                        "贝莱德",
                        "减持",
                        "药明康德",
                        "股份"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "国金证券维持药明康德买入评级：板块高景气，CXO龙头加速成长",
                "features": {
                    "keywords": [
                        "国金证券",
                        "药明康德",
                        "买入",
                        "CXO",
                        "高景气"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "天士力抗抑郁新药获批临试；海南博鳌全球特药险上线；正腾康生物完成B轮融资",
                "features": {
                    "keywords": [
                        "天士力",
                        "抗抑郁",
                        "新药",
                        "博鳌",
                        "特药险",
                        "融资"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "礼来最新财报：治疗阿尔茨海默病和糖尿病，两大潜在重磅药物计划今年递交上市申请（附PPT）",
                "features": {
                    "keywords": [
                        "礼来",
                        "财报",
                        "阿尔茨海默病",
                        "糖尿病",
                        "药物",
                        "上市申请"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "速递 | 32亿美元加码布局mRNA疫苗和疗法开发，赛诺菲收购新锐",
                "features": {
                    "keywords": [
                        "赛诺菲",
                        "mRNA",
                        "疫苗",
                        "疗法",
                        "收购"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "游戏产业将变天？北上积极调仓聚焦两大板块",
                "features": {
                    "keywords": [
                        "游戏产业",
                        "北上",
                        "调仓",
                        "板块"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "游戏"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}